| Bosentan-treated PPH patients |
Subjects n | 169 |
Duration of observation for survival | |
Mean±sd | 2.1±0.5 yrs |
Range | 0.1–3.3 yrs |
Patients lost to follow-up | 1 |
Lung transplantations | 3 |
Deaths n (%) | 20 (12)# |
Transfers to/additions of prostanoids or alternative oral PPH therapies n (%) | 39 (23)¶ |
Patients who received alternative treatment | 19 |
in addition to bosentan | |
Discontinuations of bosentan without other event or treatment | 4 |